SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Caris Life Sciences logo
5 days ago

Senior Director - Product Marketing, Oncology Therapy Selection

Caris Life Sciences

Phoenix, AZ (Unknown)Full time
Caris Life Sciences logo
5 days ago

Senior Director – Marketing, Caris MRD

Caris Life Sciences

Phoenix, AZ (Unknown)Full time
Caris Life Sciences logo
5 days ago

Senior Director - Software Marketing - Caris AI Insights

Caris Life Sciences

Irving, TX (Unknown)Full time
Caris Life Sciences logo
3 weeks ago

International Marketing Manager

Caris Life Sciences

Arizona, USA (Hybrid)Full time$108K/yr – $120K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Caris Life Sciences logo

Senior Director - Product Marketing, Oncology Therapy Selection

Caris Life Sciences

Phoenix, AZ (Unknown)

In-houseFull-timeSenior level12+ years exp.
5 days ago
Caris Life Sciences logo

Senior Director – Marketing, Caris MRD

Caris Life Sciences

Phoenix, AZ (Unknown)

In-houseFull-timeSenior level10+ years exp.
5 days ago
Caris Life Sciences logo

Senior Director - Software Marketing - Caris AI Insights

Caris Life Sciences

Irving, TX (Unknown)

In-houseFull-timeSenior level12+ years exp.
5 days ago
Caris Life Sciences logo

International Marketing Manager

Caris Life Sciences

Arizona, USA (Hybrid)

$108K/yr - $120K/yrIn-houseFull-timeMid level5+ years exp.
3 weeks ago
Caris Life Sciences logo
Caris Life Sciences

Senior Director - Product Marketing, Oncology Therapy Selection

Phoenix, AZ (Unknown)

Salary Not AvailableSenior Level12+ years expFull time

Posted 5 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and drive the Oncology Therapy Selection product marketing strategy, lead a marketing team, shape positioning and launch plans, and collaborate across R&D, Medical Affairs, access, and sales to translate clinical evidence into differentiated messaging and grow adoption.

  • Own portfolio strategy and performance metrics
  • Lead cross-functional orchestration for launches and lifecycle management

Job Description

Responsibilities

  • Develop and execute the product marketing strategy for the Oncology Therapy Selection portfolio, ensuring alignment with corporate objectives, commercial priorities, and long-term business goals.
  • Provide strategic leadership and coaching to Product Marketing Directors responsible for MI Cancer Seek® and Caris Assure™, ensuring alignment across portfolio strategy, messaging, and execution.
  • Define differentiated product positioning, value propositions, and messaging grounded in clinical utility, health economic value, and patient outcomes.
  • Lead commercialization strategies, including launch planning, market expansion initiatives, new product introductions, and lifecycle management activities.
  • Develop customer segmentation, targeting, and channel strategies that drive adoption among oncologists, community providers, health systems, and strategic partners.
  • Partner closely with Sales Leadership to develop field enablement strategies, including sales tools, training, messaging, and customer engagement resources.
  • Collaborate with Medical Affairs, Research & Development, Clinical Development, Product Management, Market Access, Business Development, and Commercial Operations to ensure alignment across product strategy, evidence generation, and commercialization efforts.
  • Translate scientific and clinical evidence into compelling marketing strategies and customer-facing communications that support product differentiation and adoption.
  • Monitor market dynamics, competitive intelligence, customer insights, and emerging clinical evidence to refine product positioning, messaging, pricing, and commercialization strategies.
  • Incorporate voice-of-customer feedback and real-world evidence into ongoing portfolio strategy and marketing initiatives.

Requirements

  • Bachelor's degree required; MBA, MPH, PhD, MD, or other advanced degree strongly preferred.
  • Twelve (12) or more years of progressive experience in product marketing, commercial strategy, or related leadership roles within healthcare, life sciences, biotechnology, diagnostics, or precision medicine.
  • Experience in oncology, molecular diagnostics, or precision medicine strongly preferred.
  • Demonstrated success leading product launches, commercialization strategies, and sustained revenue growth for complex healthcare products.
  • Strong understanding of clinical evidence generation, regulatory requirements, reimbursement, and healthcare market dynamics.
  • Proven ability to lead, develop, and mentor high-performing marketing teams.
  • Exceptional strategic thinking, executive communication, presentation, and cross-functional leadership skills.
  • Demonstrated ability to influence senior leadership and effectively manage multiple strategic initiatives in a fast-paced environment.
Caris Life Sciences logo

Caris Life Sciences

2.9 Glassdoor

Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.

Founded in 1996
Irving, Texas, USA
1.5K employees (30 in marketing)
www.carislifesciences.com
44% recommend to a friend
42% CEO approval

Traffic Signals

Monthly Visitors
54.1K
Monthly Google Ads Budget
$3.7K
Traffic Source Mix
Search
52.8%
Direct
37.3%
Referral
6.4%
Social
1.3%
Paid
2.1%

Headcount Trend

Current headcount: ~1.5K

Marketing Team

Marketing Team Size
23 (2% of company)
Median Career Experience
12.5 years
Median Tenure
4.4 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Grant Gibson, PhD
Grant Gibson, PhD
Vice President, Product Marketing
At the company for 5 years
Bailey Browder
Bailey Browder
Senior Director, Corporate Marketing
At the company for 5 years 8 months
Konnie Hermesmeyer
Konnie Hermesmeyer
Director of Strategic Marketing - Corporate Accounts
At the company for 2 years 4 months
Douglas Leonard
Douglas Leonard
Director of Biopharma Marketing
At the company for 2 years 8 months

Funding

Total Funding
$1.9B
Last Raise
$168M
Private Equity, 11 months ago

Funding History

  • Apr 2025
    Private Equity • $168M
  • Jan 2023
    Debt Financing • $400M
  • May 2021
    Private Equity • $830M

Recent News

Cannaccord Genuity Asserts Hold Stance on Caris Life Sciences, Inc. (CAI) On Oncology Pipeline Development
Dec 11, 2025 • Yahoo Finance
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
Dec 10, 2025 • PR Newswire
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Dec 4, 2025 • PR Newswire
Canaccord Genuity initiates Caris Life Sciences stock with Hold rating
Dec 2, 2025 • Investing.com
Caris Life Sciences (NASDAQ: CAI) plans Q4 2025 investor meetings at conferences
Nov 17, 2025 • Stock Titan
Caris Life Sciences to Attend Q4 2025 Investor Conferences
Nov 17, 2025 • PR Newswire
Spetzler buys Caris Life Sciences (CAI) shares worth $9,540
Nov 10, 2025 • Investing.com
Caris Life Sciences: Assessing Valuation After Strong Q3 Profit Swing and Raised 2025 Revenue Outlook
Nov 9, 2025 • simplywall.st
Why Caris Life Sciences (CAI) Raised Revenue Outlook and Tightened Governance After Record Quarterly Profit
Nov 8, 2025 • simplywall.st
Precision Oncology Alliance with Caris Life Sciences - Life Sciences Today Podcast Episode 34
Nov 7, 2025 • Healthcare IT Today
Caris Life Sciences (CAI): Revenue Forecast to Rise 21% Annually Heading Into Earnings Season
Nov 6, 2025 • simplywall.st
Why Caris Life Sciences Shares Are Dropping
Nov 5, 2025 • TipRanks
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Nov 5, 2025 • PR Newswire
Decoding Caris Life Sciences Inc (CAI): A Strategic SWOT Insight
Nov 5, 2025 • GuruFocus
Earnings call transcript: Caris Life Sciences sees 113% revenue surge in Q3 2025
Nov 5, 2025 • Investing.com
What To Expect From Caris Life Sciences Inc (CAI) Q3 2025 Earnings
Nov 4, 2025 • Yahoo Finance
Caris Life Sciences (CAI): Exploring Valuation After Recent Share Price Momentum
Nov 2, 2025 • Yahoo Finance
Caris Life Sciences announces collaborative new research on TET2
Oct 30, 2025 • Yahoo Finance
Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Oct 23, 2025 • Yahoo Finance
Caris Life Sciences (NASDAQ: CAI) sets Nov 5 webcast at 3:30 p.m. CT for quarterly results
Oct 23, 2025 • Stock Titan
Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
Oct 14, 2025 • PR Newswire
Caris Life Sciences Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Oct 9, 2025 • Investor's Business Daily
How Does Caris Life Sciences Stack Up After Recent 18.7% Drop?
Oct 3, 2025 • simplywall.st
Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue
Oct 1, 2025 • Yahoo Finance
Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms (NASDAQ:CAI)
Sep 19, 2025 • Seeking Alpha
Strong Performance Lifted Caris Life Sciences (CAI) in Q2
Sep 18, 2025 • Yahoo Finance
T.Rx Capital Launches $77.5M Fund I to Invest in Bold Sta...
Sep 18, 2025 • PharmiWeb
How Real-World Data is Transforming Tissue-Agnostic Cancer Care – Caris Life Sciences
Sep 16, 2025 • Oncodaily
Dallas-Fort Worth Metro Named ‘AI Star Hub’ in Brookings Report Mapping America’s AI Economy
Sep 12, 2025 • Dallas Innovates
Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test
Sep 11, 2025 • Yahoo Finance
Global Multi-omics Market to Grow at 16% CAGR, Driven by R&D & Precision Medicine by 2030
Sep 4, 2025 • PharmiWeb
Treeline Biosciences Inks $200M Series A Extension
Sep 3, 2025 • vcnewsdaily.com
Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic
Sep 3, 2025 • MedCity News
Treeline Biosciences: $200 Million Additional Funding Raised And First Clinical Trials Announced
Sep 3, 2025 • Pulse 2.0
Treeline Announces First Clinical Trials and Secures $200M in Additional Funding
Sep 3, 2025 • Venture Capital Firms
Caris Life Sciences: A Closer Look at Opportunities, Roadblocks for Widespread Adoption of AI-Based Precision Oncology Tools
Sep 2, 2025 • The Capitol Forum
Life Science Tools Market to Grow at a CAGR of 10.81% from 2025 to 2032 | SkyQuest Technology Consulting
Aug 28, 2025 • PR Newswire
Can AI make clinical trials better?
Aug 23, 2025 • Investing.com
David Spetzler Highlights New Data Validating MI Cancer Seek® Assay from Caris Life Science
Aug 22, 2025 • Oncodaily
Varro Life Sciences Expands in St. Louis, Opening Lab and R&D Facility, Investing $42.5 Million and Creating 33 Jobs
Aug 21, 2025 • EIN Presswire
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®
Aug 18, 2025 • BioSpace
Caris Life Sciences Earns Relative Strength Rating Upgrade
Aug 15, 2025 • Investor's Business Daily
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®
Aug 15, 2025 • PR Newswire
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®
Aug 15, 2025 • MarketScreener
Biotech Isn’t Partaking In The IPO Rebound
Aug 15, 2025 • Crunchbase News
Caris Life Sciences publishes study in Oncotarget on MI Cancer Seek
Aug 15, 2025 • thefly.com
Transcript : Caris Life Sciences, Inc., Q2 2025 Earnings Call, Aug 12, 2025
Aug 14, 2025 • MarketScreener
Stocks To Watch: Caris Life Sciences Sees Relative Strength Rating Jump To 86
Aug 13, 2025 • Investor's Business Daily
New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups
Aug 13, 2025 • PR Newswire
Caris Life Sciences stock price target raised to $45 from $38 at BTIG
Aug 13, 2025 • Investing.com
Caris Life Sciences publishes results of antibody-drug study in breast cancer
Aug 13, 2025 • thefly.com
Caris Life Sciences Says Study Validates Optimal Sequencing in Treating Breast Cancer
Aug 13, 2025 • MarketScreener
Earnings call transcript: Caris Life Sciences sees 81% revenue growth in Q2 2025
Aug 12, 2025 • Investing.com
Caris Life Sciences Trying To Close In On Key Technical Benchmark
Aug 12, 2025 • Investor's Business Daily
Caris Life Sciences Reports Second Quarter 2025 Financial Results
Aug 12, 2025 • Newswise
Caris Life Sciences reports Q2 EPS ($7.97) with items, consensus (22c)
Aug 12, 2025 • thefly.com
Pace Life Sciences Debuts Enhanced cGMP Manufacturing Capabilities to Support Increasing Demand for Sterile Injectables
Aug 12, 2025 • Newswire
Caris Life Sciences Reports Second Quarter 2025 Financial Results
Aug 12, 2025 • PR Newswire
Cancer Biomarkers Market Industry Trends and Global Forecasts to 2035: Close to 100 Novel Cancer Biomarker Solutions Leveraging NGS Technology - ResearchAndMarkets.com
Aug 11, 2025 • Business Wire
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
Aug 11, 2025 • Business Wire
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor
Aug 6, 2025 • PR Newswire
Caris Life Sciences Sees Relative Strength Rating Improve To 74
Aug 6, 2025 • Investor's Business Daily
Caris Life Sciences publishes new study on AI-based image analysis model
Aug 6, 2025 • thefly.com
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed
Aug 5, 2025 • PR Newswire
Enlil Announces Seven Strategic Partnerships to Accelerate MedTech Innovation and Customer FDA Clearance Success
Jul 31, 2025 • PR Newswire
Cancer Pain Market Size to Reach USD 12031.1 Million Globally by 2035: Latest Report by Vantage Market Research
Jul 31, 2025 • PharmiWeb
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025 • Business Wire
Cancer Biomarkers Market Forecast Report 2025-2035: Over 685 Clinical Trials Focused on Novel Cancer Biomarkers Underway
Jul 30, 2025 • Research and Markets
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 – Company Announcement
Jul 23, 2025 • Financial Times
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 23, 2025 • Yahoo Finance
AI TechBio Pioneer Caris Life Sciences Sets Q2 Earnings Call: Key Details for Precision Medicine Investors
Jul 23, 2025 • Stock Titan
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 23, 2025 • BioSpace
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 23, 2025 • PR Newswire
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 23, 2025 • Morningstar.com
June Hits 3-Year High In Unicorn Births Across AI, Robotics And More
Jul 23, 2025 • Crunchbase News
Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis
Jul 23, 2025 • BioSpace
Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis
Jul 22, 2025 • PR Newswire
Next-Generation AI in Life Sciences Market Sees 54% Uptake by Biopharma in 2025
Jul 22, 2025 • BioSpace
Bioavailability Enhancement Technologies and Services Market Industry Trends and Global Forecasts to 2035: Bioavailability Sector Set to Reach USD 10.22 Billion by 2035
Jul 21, 2025 • Research and Markets
ADIA invests $200 million in Micro Life Sciences
Jul 20, 2025 • Hindu Business Line
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences
Jul 19, 2025 • Benzinga
Antibody Discovery Market Size to Surpass USD 20.4 Bn by 2034 Fueled by Precision Medicine and Biotech Innovation
Jul 17, 2025 • BioSpace
Private Financing for Life Science Tools and Dx Firms Rises in H1 2025 Despite Tariff, Funding Chaos
Jul 16, 2025 • GenomeWeb
Wolfe Research initiates Caris Life Sciences stock with Outperform rating
Jul 14, 2025 • Investing.com
BofA Securities initiates coverage on Caris Life Sciences stock with Buy rating
Jul 13, 2025 • Investing.com
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection
Jul 8, 2025 • PR Newswire
Wafik El-Deiry: Collaborative Manuscript by Jim Abraham et al. Colleagues at Caris Life Sciences and the Caris Precision Oncology Alliance
Jul 3, 2025 • Oncodaily
Major Stock Purchases Shake Up Caris Life Sciences!
Jun 23, 2025 • TipRanks
Should You Buy Caris Life Sciences Stock After The CAI IPO?
Jun 23, 2025 • Barchart.com
Should You Buy Caris Life Sciences Stock After the CAI IPO?
Jun 23, 2025 • Yahoo Finance
Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools
Jun 22, 2025 • MedCity News
Caris Life Sciences indicated to open at $30, IPO priced at $21 per share
Jun 20, 2025 • Yahoo Finance
Caris settles IPO at $21, trading starts at $28
Jun 20, 2025 • BioWorld MedTech
Caris Life Sciences: Momentum Returns In The IPO Market (NASDAQ:CAI)
Jun 20, 2025 • Seeking Alpha
Cancer Testing Company Caris Goes Public in $494M IPO
Jun 18, 2025 • Medical Device and Diagnostic industry
Caris Life Sciences spikes by over 30% in IPO debut, embraces AI as future of oncology
Jun 18, 2025 • Dallas News
Caris Life Sciences trades higher on market debut (CAI)
Jun 18, 2025 • Seeking Alpha
Caris Life Sciences Rings the Opening Bell
Jun 18, 2025 • Nasdaq
Sixth Street-backed Caris Life valued at $7.7 billion in strong Nasdaq debut
Jun 18, 2025 • Reuters
Caris Life Sciences Prices $494M IPO
Jun 18, 2025 • 360Dx